The two biggest biopharmaceutical initial public offerings in the US so far in 2023 occurred during the first week of May, although the largest of the two was a consumer health care spinout from a drug maker – Johnson & Johnson’s separation of Kenvue Inc. from its remaining pharmaceutical and medical device businesses. Kenvue grossed $3.8bn from the sale of 172.8 million shares at $22 each on 3 May, while Acelyrin, Inc. sold 30 million shares at $18 each to gross $540m on 4 May.
Both offerings – the seventh and eighth biopharma IPOs of 2023 – were well received by investors. Kenvue closed its first day of trading up 22.3% at $26.90 on 4 May. Acelyrin closed at $23.50 on 5 May, up 30.6%, after pricing its IPO at the top end of a proposed $16 to $18 price range and increasing the size of the offering from a planned 26.5 million shares to fund the late-stage development program for its interleukin-17A inhibitor izokibep
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?